Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Operating Income: 2015-2024

Historic Operating Income for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$96.8 million.

  • UroGen Pharma's Operating Income fell 56.09% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$133.4 million, marking a year-over-year decrease of 59.32%. This contributed to the annual value of -$96.8 million for FY2024, which is 47.68% down from last year.
  • As of FY2024, UroGen Pharma's Operating Income stood at -$96.8 million, which was down 47.68% from -$65.5 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Operating Income registered a high of -$65.5 million during FY2023, and its lowest value of -$126.7 million during FY2020.
  • Over the past 3 years, UroGen Pharma's median Operating Income value was -$79.0 million (recorded in 2022), while the average stood at -$80.5 million.
  • As far as peak fluctuations go, UroGen Pharma's Operating Income grew by 27.18% in 2021, and later plummeted by 47.68% in 2024.
  • Over the past 5 years, UroGen Pharma's Operating Income (Yearly) stood at -$126.7 million in 2020, then climbed by 27.18% to -$92.3 million in 2021, then climbed by 14.36% to -$79.0 million in 2022, then rose by 17.09% to -$65.5 million in 2023, then slumped by 47.68% to -$96.8 million in 2024.